Advertising
Showing 1 to 15 of 81 entries
PAST TOP PICK
(A Top Pick Sep 30/20, Up 29%) Their primary franchise is going of patent in a couple years. They have been working on diluting its effect, especially with their purchase of Allergan. Other franchises are getting to billion dollar franchises too. The clock is ticking. FDA detemined they have to put a warning of possible heart problems, which led to a sell off. This indicates that the markets are getting nervous. Cheap, good dividend, but always have to be alert to the future.
0
BUY
Has the lowest PE is this space, and yet pays the highest dividend yield. It's quietly moved up in anticipation of its rheumatory arthritis drug getting FDA approval.
0
COMMENT
https://finance.yahoo.com/news/abbvies-abbv-rinvoq-snda-decision-114811600.html AbbVie announced that the FDA won't grant a decision on the application of AbbVie's arthritis drug, Rinvoq (though it has been approved in Europe). He's very disappointment that AbbVie has not gotten the FDA vote through. If Runvoq does not pass, it could be very bad for Abbvie. He is very concerned.
0
BUY

Trades at 10x earnings. Fine fundamentals. Owns Humera, a hugely profitable drug. ABBV bought Allergan to dilute the dependence on Humera revenues. That's when he bought ABBV, because the company became less risky. A fine 4.5% dividend. Caveat: in 2023, Humera goes off-patent, so ABBV has been busy replacing these future lost revenues (so they bought Allergan). They also have been developing and acquiring new drugs. Worries of going off-patent are already built in share prices, so the worry is in the past.

0
BUY

A great holding. Pays nearly a 5% dividend yield. They bought Allergan some years ago. Humera used to be a big chunk of company revenues, but is now lower and more comfortable. Cash flow is strong. Earnings valuation is attraction. Caveat: humera goes off patent in 2023, so this will impact Abbvie's revenue stream. However, ABBV is smart by lowering the impact of humera by developing other drugs that bring in $1 billion revenues. The humera factor is fully discounted in the current Abbvie price. So, he would absolutely buy ABBV. You're now buying it at a 20% discount if ABBV didn't have that patent-expiration overhang.

0
BUY

There are some fears of loosing patent protection with Humera, but patients seem to be want to stick with the brand name. When they acquired Allergan, they got the botox franchise, which is a reopening play. 4.5% yield. A good long term play. They have a good pipeline as well.

0

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
TOP PICK
Stockchase Research Editor: Michael O'Reilly ABBV is one of the highest quality pharma stocks you can own with a $194 billion market cap and is a good defensive holding paying an excellent dividend (backed by a payout ratio of 50% of cash flow). Best known for its Crohn's disease treatment Humira, which provided over $19 billion in revenue last year. We would buy this with a stop loss at $90, looking to achieve $125 -- upside potential over 11%. Not a growth stock, but a good dividend payer. Yield 4.45% (Analysts’ price target is $122.17)
0
PAST TOP PICK

(A Top Pick May 12/20, Up 24%) He's sticking with it. There's more upside to come. Their biggest product was Humera, a massive drug. A few years ago, they bought Allergan and their Botox drug, which reduced company dependence on Humera for company revenues. ABBV has some new drugs in the pipeline that are reaching $1 billion in sales, so this further spreads the risk away from Humera. It trades at a cheap 9x PE and pays a 5% dividend. Warning: in 2023, Humera goes off patent and that will mean a challenge for ABBV to replace that revenue stream (Humera makes up 32% of all revenues, though it used to be 65% before Botox).

0
BUY on WEAKNESS
There was an issue with a key drug of theirs today (the FDA delayed reviewing it for 3 months). He suspects this is just a speed bump, expects a downgrade or two tomorrow, but this is a buying opportunity.
0
BUY
It beat earnings, but has struggled the past week. It stalled because people can't get their Botox (a big part of their business) during the lockdown, but ABBV's migraine franchise is fine and the drugs replacing Humera, their big product, are working. Also, this is cheap at 8x earnings and it pays a 5% yield. A bargain now.
0
TOP PICK

Large cap biotech. Humera generates $20B a year in revenue. Exceptional job at using that cashflow to diversify, as in buying Allergan. 15% EPS, clean balance sheet. Its value will eventually be realized. Yield is 5%. (Analysts’ price target is $121.05)

0
BUY

All big pharmas have been treading water. Patent legislation left them with a leaky boat. He's gravitated toward the bio-pharmas. His favourite in that space is AbbVie, as it's good on fundamentals and financials, inexpensive, very fine dividend, great cashflow generator.

0
COMMENT
This discuss their immunology franchise on Monday. If they can present good numbers on new drugs to replace Humera--their biggest-selling drug, but is losing patent protection soon--this will take pressure off this drug and this stock will climb futher. ABBV has a lot of growth and pays a good yield.
0
BUY
You would own it for the strong yield at 5.25%. Valuation is quite cheap relative to peers. Good earnings growth and dividend growth. They raised their guidance which is positive. The split congress helps this name since pushing drug prices down will be harder.
0
BUY

Likes it. A spin-off of Abbott Labs. They have made a purchase of Allergan that diluted the concentration of Humira. The company will get its legs so buy it and be patient.

0
Showing 1 to 15 of 81 entries

AbbVie Inc.(ABBV-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 11

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 12

Stockchase rating for AbbVie Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

AbbVie Inc.(ABBV-N) Frequently Asked Questions

What is AbbVie Inc. stock symbol?

AbbVie Inc. is a American stock, trading under the symbol ABBV-N on the New York Stock Exchange (ABBV). It is usually referred to as NYSE:ABBV or ABBV-N

Is AbbVie Inc. a buy or a sell?

In the last year, 12 stock analysts published opinions about ABBV-N. 11 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for AbbVie Inc..

Is AbbVie Inc. a good investment or a top pick?

AbbVie Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for AbbVie Inc..

Why is AbbVie Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is AbbVie Inc. worth watching?

12 stock analysts on Stockchase covered AbbVie Inc. In the last year. It is a trending stock that is worth watching.

What is AbbVie Inc. stock price?

On 2021-10-19, AbbVie Inc. (ABBV-N) stock closed at a price of $107.57.